KFRX06 / KeifeRx, Amneal - LARVOL DELTA

Synergistic Effects of Multi-Kinase Inhibition on LRRK2-G2019S and Alpha-Synuclein Pathologies in Models of Parkinson's Disease. (PubMed, Biomedicines) - "BK40196 may provide a comprehensive and synergistic therapeutic approach that addresses multiple mechanisms to reduce the pathologies related to LRRK2 G2019S and/or SNCA in PD. The multiple pathologies of PD necessitate a holistic approach that simultaneously targets inflammation and autophagy and LRRK2 inhibition."

Journal • CNS Disorders • Inflammation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • KIT • LRRK2 • SNCA

KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease (Businesswire) - "Under the agreement, KeifeRx will conduct a research program intended to generate key pre-IND outputs to support Amneal’s evaluation of KFRX06 and inform potential next-stage development. Financial terms of the agreement were not disclosed."

Licensing / partnership • Parkinson's Disease